WO2001068882A3 - Procedes permettant d'ameliorer la recombinaison homologue - Google Patents

Procedes permettant d'ameliorer la recombinaison homologue Download PDF

Info

Publication number
WO2001068882A3
WO2001068882A3 PCT/US2001/007870 US0107870W WO0168882A3 WO 2001068882 A3 WO2001068882 A3 WO 2001068882A3 US 0107870 W US0107870 W US 0107870W WO 0168882 A3 WO0168882 A3 WO 0168882A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
homologous recombination
alteration
antibody
end joining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/007870
Other languages
English (en)
Other versions
WO2001068882A2 (fr
Inventor
Evguenii Ivanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Priority to AT01918578T priority Critical patent/ATE525472T1/de
Priority to MXPA02009044A priority patent/MXPA02009044A/es
Priority to JP2001567365A priority patent/JP2003526376A/ja
Priority to EP01918578A priority patent/EP1263972B1/fr
Priority to CA002403113A priority patent/CA2403113A1/fr
Priority to DK01918578.4T priority patent/DK1263972T3/da
Priority to AU2001245637A priority patent/AU2001245637A1/en
Publication of WO2001068882A2 publication Critical patent/WO2001068882A2/fr
Publication of WO2001068882A3 publication Critical patent/WO2001068882A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Led Devices (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

L'invention concerne un procédé permettant de favoriser une modification sur un site sélectionné dans un ADN cible, par exemple, l'ADN chromosomique d'une cellule. Le procédé consiste à fournir à un site: (a) une séquence d'ADN à double hélice comprenant une séquence d'ADN sélectionnée; (b) un agent améliorant la recombinaison homologue, par exemple, une protéine Rad52 ou un fragment fonctionnel de celle-ci; et (c) un agent inhibant un joint d'extrémité non-homologue, par exemple, un agent qui inactive Ku, tel qu'un anticorps anti-Ku ou un polymère ou un oligomère se fixant à Ku; puis à permettant le déclenchement de la modification. De préférence, l'agent inhibant le joint d'extrémité non homologue, par exemple un agent inactivant Ku, tel qu'un anticorps anti-Ku, est fourni localement. Les composants (a), (b), et (c) peuvent être introduits ensemble, de préférence, ou séparément.
PCT/US2001/007870 2000-03-14 2001-03-13 Procedes permettant d'ameliorer la recombinaison homologue Ceased WO2001068882A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT01918578T ATE525472T1 (de) 2000-03-14 2001-03-13 Verfahren zur homologen rekombination
MXPA02009044A MXPA02009044A (es) 2000-03-14 2001-03-13 Metodos para mejorar una recombinacion homologa.
JP2001567365A JP2003526376A (ja) 2000-03-14 2001-03-13 相同組換えを改善する方法
EP01918578A EP1263972B1 (fr) 2000-03-14 2001-03-13 Procedes permettant d'ameliorer la recombinaison homologue
CA002403113A CA2403113A1 (fr) 2000-03-14 2001-03-13 Procedes permettant d'ameliorer la recombinaison homologue
DK01918578.4T DK1263972T3 (da) 2000-03-14 2001-03-13 Fremgangsmåde til homolog rekombination
AU2001245637A AU2001245637A1 (en) 2000-03-14 2001-03-13 Methods of improving homologous recombination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/525,160 US6569681B1 (en) 2000-03-14 2000-03-14 Methods of improving homologous recombination
US09/525,160 2000-03-14

Publications (2)

Publication Number Publication Date
WO2001068882A2 WO2001068882A2 (fr) 2001-09-20
WO2001068882A3 true WO2001068882A3 (fr) 2002-03-14

Family

ID=24092175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007870 Ceased WO2001068882A2 (fr) 2000-03-14 2001-03-13 Procedes permettant d'ameliorer la recombinaison homologue

Country Status (10)

Country Link
US (1) US6569681B1 (fr)
EP (1) EP1263972B1 (fr)
JP (1) JP2003526376A (fr)
AT (1) ATE525472T1 (fr)
AU (1) AU2001245637A1 (fr)
CA (1) CA2403113A1 (fr)
DK (1) DK1263972T3 (fr)
MX (1) MXPA02009044A (fr)
TR (1) TR200202196T2 (fr)
WO (1) WO2001068882A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524366A (en) * 2000-07-27 2005-12-23 Univ Delaware Methods for enhancing targeted gene alteration using oligonucleotides
DK1395669T3 (da) * 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
CA2473741C (fr) * 2002-01-18 2015-12-22 Morphotek, Inc. Methode de generation de cellules genetiquement modifiees pour la regulation et l'analyse de genes specifiques d'un locus
GB0214896D0 (en) * 2002-06-27 2002-08-07 Novartis Forschungsstiftung Gene for increased somatic recombination
FR2846337B1 (fr) * 2002-10-28 2007-06-22 Centre Nat Rech Scient Procede pour inserer un acide nucleique d'interet dans une cellule procaryote ou eucaryote par recombinaison homologue
WO2004061077A2 (fr) * 2002-12-24 2004-07-22 North Carolina State University Augmentation de la production de gametes dans le cadre d'une commutation genique
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
JP4050712B2 (ja) 2004-02-27 2008-02-20 独立行政法人科学技術振興機構 相同組換えを行わせる方法
EP3351637B1 (fr) * 2004-04-02 2020-06-10 DSM IP Assets B.V. Mutants fongiques filamenteux avec une efficacité améliorée de recombinaison homologue
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
JP4625318B2 (ja) * 2004-12-06 2011-02-02 財団法人野田産業科学研究所 相同組換え頻度が上昇した形質転換菌
EP2166100B1 (fr) 2005-03-08 2012-07-18 BASF Plant Science GmbH Séquences introniques facilitant l'expression
EP1871868A2 (fr) 2005-04-15 2008-01-02 North Carolina State University Procédés et compositions pour moduler l'adhésion et la résistance au stress chez des bactéries
JP2007222055A (ja) * 2006-02-22 2007-09-06 Noda Inst For Scient Res 染色体領域欠失株の作製方法
JP2008263927A (ja) * 2007-04-25 2008-11-06 Noda Inst For Scient Res 染色体大領域の欠失方法
JP5497632B2 (ja) * 2007-05-09 2014-05-21 ノボザイムス アクティーゼルスカブ 関心対象のポリペプチドを産生するライブラリークローンの選択に適した発現クローニング法
NZ599338A (en) 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
WO2011017315A2 (fr) * 2009-08-03 2011-02-10 Recombinetics, Inc. Procédés et compositions pour modification de gène ciblé
CA2769822C (fr) 2009-08-13 2019-02-19 The Johns Hopkins University Methodes de modulation de la fonction immunitaire
CN102791865B (zh) * 2009-12-21 2015-07-01 凯津公司 用于转染原生质体的改进技术
WO2011078662A1 (fr) * 2009-12-21 2011-06-30 Keygene N.V. Arndb pour la modification génétique améliorée d'adn de plante
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
WO2012168307A2 (fr) * 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Efficacité améliorée de recombinaison par inhibition d'une réparation de l'adn par nhej
EP2814969A4 (fr) * 2012-02-10 2016-02-17 Univ Minnesota Assimiliation de l'adn
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
WO2015066205A1 (fr) * 2013-10-29 2015-05-07 Rutgers, The State University Of New Jersey Organisme à modification génétique rapide, systèmes d'édition précise du génome et manipulation génétique ciblée par recombinaison homologue améliorée
ES2811974T3 (es) 2014-07-29 2021-03-15 Novartis Ag Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
EP3200816A1 (fr) 2014-09-29 2017-08-09 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la mucopolysaccharidose de type iiib (mpsiiib)
ES2847252T3 (es) 2016-02-22 2021-08-02 Caribou Biosciences Inc Procedimientos de modulación de resultados de reparación de ADN
WO2018134784A1 (fr) 2017-01-20 2018-07-26 Novartis Ag Polythérapie pour le traitement du cancer
WO2018134782A1 (fr) 2017-01-20 2018-07-26 Novartis Ag Polythérapie pour le traitement du cancer
JP7084021B2 (ja) * 2018-01-24 2022-06-14 公立大学法人大阪 ターゲティングベクター
US20210244821A1 (en) 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1998030902A1 (fr) * 1997-01-13 1998-07-16 Kudos Pharmaceuticals Limited Dosages, agents, therapie et diagnostic lies a la modulation de l'activite de reparation de l'adn cellulaire
WO1998030903A1 (fr) * 1997-01-13 1998-07-16 Kudos Pharmaceuticals Limited Procedes et moyens lies a l'integration de retrovirus et de retrotransposon
WO1999025829A2 (fr) * 1997-11-13 1999-05-27 Curagen Corporation Proteine cdk2 et complexes a base de proteine cdk2
WO2000012716A2 (fr) * 1998-09-02 2000-03-09 Pioneer Hi-Bred International, Inc. ORTHOLOGUE Ku70 DU MAIS ET UTILISATIONS ASSOCIEES
WO2000068404A1 (fr) * 1999-05-05 2000-11-16 Pioneer Hi-Bred International, Inc. Orthologue du mais rad50 et ses applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010908A (en) 1992-08-21 2000-01-04 The Regents Of The University Of California Gene therapy by small fragment homologous replacement
AU4115693A (en) * 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US5780296A (en) 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
KR100570935B1 (ko) * 1997-01-17 2006-04-13 맥시겐, 인크. 반복적 서열 재조합에 의한 전세포 및 유기체의 개량 방법
DE19755952C1 (de) 1997-12-16 1998-12-10 Curt Niebling Dünnwandiges, elektro-magnetisch abschirmendes, tiefgezogenes Formteil, Verfahren zu dessen Herstellung, und ein bei diesem Verfahren einsetzbares Zwischenprodukt
US6441158B1 (en) 1997-12-31 2002-08-27 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1998030902A1 (fr) * 1997-01-13 1998-07-16 Kudos Pharmaceuticals Limited Dosages, agents, therapie et diagnostic lies a la modulation de l'activite de reparation de l'adn cellulaire
WO1998030903A1 (fr) * 1997-01-13 1998-07-16 Kudos Pharmaceuticals Limited Procedes et moyens lies a l'integration de retrovirus et de retrotransposon
WO1999025829A2 (fr) * 1997-11-13 1999-05-27 Curagen Corporation Proteine cdk2 et complexes a base de proteine cdk2
WO2000012716A2 (fr) * 1998-09-02 2000-03-09 Pioneer Hi-Bred International, Inc. ORTHOLOGUE Ku70 DU MAIS ET UTILISATIONS ASSOCIEES
WO2000068404A1 (fr) * 1999-05-05 2000-11-16 Pioneer Hi-Bred International, Inc. Orthologue du mais rad50 et ses applications

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CRITCHLOW S E ET AL: "MAMMALIAN DNA DOUBLE-STRAND BREAK REPAIR PROTEIN XRCC4 INTERACTS WITH DNA LIGASE IV", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 7, no. 8, 1 August 1997 (1997-08-01), pages 588 - 598, XP002065034, ISSN: 0960-9822 *
KABOTYANSKI ELENA B ET AL: "Double-strand break repair in Ku86- and XRCC4-deficient cells.", NUCLEIC ACIDS RESEARCH, vol. 26, no. 23, 1 December 1998 (1998-12-01), pages 5333 - 5342, XP002178016, ISSN: 0305-1048 *
MILNE G TODD ET AL: "Mutations in two Ku homologs define a DNA end-joining repair pathway in Saccharomyces cerevisiae.", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 8, 1996, pages 4189 - 4198, XP002178015, ISSN: 0270-7306 *
PETRINI J H J: "The Mammalian Mre11-Rad50-Nbs1 Protein Complex: Integration of Functions in the Cellular DNA-Damage Response", AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO,, US, vol. 64, 6 April 1999 (1999-04-06), pages 1264 - 1269, XP002150324, ISSN: 0002-9297 *
TEO SOO-HWANG ET AL: "Lif1p targets the DNA ligase Lig4p to sites of DNA double-strand breaks.", CURRENT BIOLOGY, vol. 10, no. 3, 10 February 2000 (2000-02-10), pages 165 - 168, XP002178014, ISSN: 0960-9822 *
TOMKINSON A E ET AL: "STRUCTURE AND FUNCTION OF MAMMALIAN DNA LIGASES", MUTATION RESEARCH, AMSTERDAM, NL, vol. 407, no. 1, 1998, pages 1 - 9, XP002065035, ISSN: 0027-5107 *
TSUKAMOTO Y ET AL: "Hdf1, a yeast Ku-protein homologue, is involved in illegitimate recombination, but not in homologous recombination", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 24, no. 11, 1996, pages 2067 - 2072, XP002170162, ISSN: 0305-1048 *

Also Published As

Publication number Publication date
US6569681B1 (en) 2003-05-27
EP1263972A2 (fr) 2002-12-11
TR200202196T2 (tr) 2003-01-21
EP1263972B1 (fr) 2011-09-21
MXPA02009044A (es) 2003-04-25
AU2001245637A1 (en) 2001-09-24
ATE525472T1 (de) 2011-10-15
DK1263972T3 (da) 2012-01-02
CA2403113A1 (fr) 2001-09-20
JP2003526376A (ja) 2003-09-09
WO2001068882A2 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
WO2001068882A3 (fr) Procedes permettant d'ameliorer la recombinaison homologue
WO2003014303A3 (fr) Interactions moleculaires dans les cellules
WO2005003294A3 (fr) Additions de code genetique d'aminoacide reactif artificiel
WO2005044367A3 (fr) Procede et appareil permettant la permeabilisation de cellules
WO2003008622A3 (fr) Amplification exponentielle d'acides nucleiques au moyen d'endonucleases de coupure
WO2002077264A3 (fr) Procede de transfection en reseau et utilisation associee
WO2002090539A3 (fr) Compositions, methodes et trousses permettant d'isoler des acides nucleiques au moyen de tensioactifs et de proteases
WO2002084250A3 (fr) Procedes de detection par spectrometrie de masse et quantification de proteines cibles specifiques dans des echantillons biologiques complexes
WO2002026789A3 (fr) Sequences nucleotidiques mediatrices de la fertilite male et procede d'utilisation associe
AU2002252297A1 (en) Methods and tools for nucleic acid sequence analysis selection and generation
AU2003302134A1 (en) Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
WO2002004666A3 (fr) Décondensation de l'adn
WO2004037198A3 (fr) Induction de la mort de cellules tumorales provoquee par un anticorps
WO2005047462A3 (fr) Systeme universel de commande d'amplification d'acides nucleiques
WO2000040757A3 (fr) Procede d'identification d'acides nucleiques
WO2001066752A3 (fr) Genes specifiques de la reproduction
WO2004079332A3 (fr) Composition et methode permettant d'introduire plus efficacement une substance cible dans une cellule
AU2002311778A1 (en) Prostate cancer-related compositions, methods and kits based on dna macroarray protemics platforms
WO2006116893A3 (fr) Procede d'analyse spectrometrique de masse
WO2003029409A3 (fr) Procedes permettant de produire, selectionner et identifier des composes fixant une molecule cible
WO2002018575A3 (fr) Genes exprimes dans le cycle cellulaire
WO2003016537A3 (fr) Procede destine a la reparation d'un arn mutant, a partir d'un adn presentant des defauts genetiques, et a la mort programmee de cellules tumorales par trans-epissage d'arn et procede d'identification d'arn cellulaire naturellement trans-episse
WO2003030719A3 (fr) Procedes et trousses a utiliser pour selectionner des methodes pour traiter un cancer
WO2003064623A3 (fr) Methodes et vecteurs permettant de faciliter la recombinaison a un site specifique
WO2002086505A3 (fr) Analyse intracellulaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2403113

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 567365

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009044

Country of ref document: MX

Ref document number: 2002/02196

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2001918578

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001918578

Country of ref document: EP